| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 |
VIRALYTICS LIMITED (VLA)
Stock Code: VLA
Listing Date: 1986-10-15 00:00:00
Website: http://www.viralytics.com
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
Intellectual property and investment company operating in the health care industry. In addition to the companies it invests in, Viralytics has a number of active projects at various stages of development - these include treatments for dermatological conditions as well as cancer therapies. Viralytics's strategy is to add shareholder value through the licensing and commercialisation of medical produ
Address:
66 Eagle Street, Level 11, McCullough Robertson
BRISBANE
NSW 4001
Phone: (02) 9499 3200
Fax: (02) 9499 3300
Executives & Directors
Mr Bryan Dulhunty, Executive Chairman, Finance Director
Prof. Darren Shafren, Director
Dr Phillip Altman, Executive Director
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
VLA - Approval to conduct Phase I Study - Mr Bryan Dulhunty, Executive Chairman
|
|
Thu, 18 Jan 2007 01:00PM |
| Annual General Meeting | Tue, 18 Nov 2008 11:00AM |
|
| Full Year Results | Fri, 29 Aug 2008 | |
| Interim Results | Thu, 28 Feb 2008 | |
| Annual General Meeting | Tue, 27 Nov 2007 10:00AM |
|
| Full Year Results | Fri, 31 Aug 2007 | |
| Interim Results | Tue, 27 Feb 2007 |
VIRALYTICS LIMITED (VLA)
| USA manufacture of CAVATAK | Mon, 30 Jun 2008 |
| Ceasing to be a substantial holder for ALT | Wed, 21 May 2008 |
| European Notice of Allowance on Core Technology | Tue, 20 May 2008 |
| Change in substantial holding for ALT | Fri, 2 May 2008 |
| Appendix 4C - quarterly | Mon, 28 Apr 2008 |
| USA patent granted | Wed, 23 Apr 2008 |
| Change in substantial holding for ALT | Mon, 7 Apr 2008 |
| First patient received Cavatak infusion in Phase 1 IV trial | Fri, 14 Mar 2008 |
| Change in substantial holding for ALT | Tue, 4 Mar 2008 |
| section 708A notice | Fri, 28 Dec 2007 |
| Appendix 3B | Fri, 28 Dec 2007 |
| Share Purchase Plan update | Fri, 21 Dec 2007 |
| Placement | Wed, 19 Dec 2007 |
| Trading Halt | Mon, 17 Dec 2007 |
| Share Purchase Plan documents sent to shareholders | Thu, 6 Dec 2007 |
| Shareholder update document | Thu, 6 Dec 2007 |
| Share Purchase Plan | Fri, 30 Nov 2007 |
| Phase I IV trial patient selection | Wed, 28 Nov 2007 |
| Chairman`s Address to Shareholders | Tue, 27 Nov 2007 |
| Results of Meeting | Tue, 27 Nov 2007 |
| Director Appointment/Resignation | Mon, 26 Nov 2007 |
| Response to ASX Share Price Query | Mon, 12 Nov 2007 |
| Appendix 4C - quarterly | Mon, 29 Oct 2007 |
| Notice of Annual General Meeting/Proxy Form | Mon, 29 Oct 2007 |
| Annual Report to shareholders | Mon, 29 Oct 2007 |
| Ceasing to be a substantial holder | Fri, 26 Oct 2007 |
| Change in substantial holding | Wed, 10 Oct 2007 |
| Date of Annual General Meeting | Wed, 3 Oct 2007 |
| Clincial trial progresses to 10 fold higher dosing level | Wed, 5 Sep 2007 |
| Annual Report and appendix 4e | Fri, 31 Aug 2007 |
| Change in substantial holding | Wed, 15 Aug 2007 |
| Appendix 4C - quarterly | Tue, 31 Jul 2007 |
| Constitution | Tue, 31 Jul 2007 |
| Change in substantial holding | Tue, 17 Jul 2007 |
| Initial Director`s Interest Notice | Mon, 16 Jul 2007 |
| Appointment of Executive Director | Thu, 12 Jul 2007 |
| Form 603 & Form 605 | Wed, 4 Jul 2007 |
| Form 605 & Form 603 | Wed, 4 Jul 2007 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.